Roche
Big PharmaSwiss pharma-diagnostics leader known for oncology and diagnostics integration. Key franchises include Tecentriq, Hemlibra, and Ocrevus. Pioneer in personalized medicine.
FDA Novel Drug Designations
(2016-2024)See 13 novel approvals →
Roche at a Glance
- Leading 21 drug targets across portfolio
- Fast trial execution (30 months median completion)
Upcoming FDA Decisions
Full Calendar →Roche's Key Drugs
Roche's core commercial portfolio centers on OCREVUS, VABYSMO, HEMLIBRA, spanning Oncology and Immunology — its most strategically important drugs approved in the last 15 years.
Relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease)
Neovascular Age-Related Macular Degeneration
Hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors
Non-Small Cell Lung Cancer
Metastatic Breast Cancer
Roche's Recent FDA Approvals
Roche secured 2 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
Roche's Therapeutic Areas
Roche's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology, across 20 biologic and 10 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Roche's Top Competitors
Roche's closest competitors by therapeutic-area and drug-target overlap include AbbVie, Eli Lilly, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Roche Pipeline Snapshot
Roche has 1037 active clinical programs from ClinicalTrials.gov — 333 Phase 3, 274 Phase 2 and 430 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 281/420 completed
- • Speed: 30 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (17)
Discontinued (0)
Company Info
- First Approval
- 1941-07-15
- Latest
- 2026-08-20
- Applications
- 119
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges